MCID: CYT005
MIFTS: 40

Cytomegalovirus Retinitis malady

Rare diseases category

Aliases & Classifications for Cytomegalovirus Retinitis

About this section

Aliases & Descriptions for Cytomegalovirus Retinitis:

Name: Cytomegalovirus Retinitis 45 65


Classifications:



Summaries for Cytomegalovirus Retinitis

About this section
Wikipedia:68 Cytomegalovirus retinitis, also known as CMV retinitis, is an inflammation of the retina of the eye that... more...

MalaCards based summary: Cytomegalovirus Retinitis is related to systemic lupus erythematosus and tuberculosis. An important gene associated with Cytomegalovirus Retinitis is CD9 (CD9 Molecule), and among its related pathways are Calcineurin-regulated NFAT-dependent transcription in lymphocytes and IL-10 Pathway. The drugs ganciclovir and ganciclovir sodium have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and t cells, and related mouse phenotypes are respiratory system and tumorigenesis.

Related Diseases for Cytomegalovirus Retinitis

About this section

Diseases related to Cytomegalovirus Retinitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 271)
idRelated DiseaseScoreTop Affiliating Genes
1systemic lupus erythematosus30.2HLA-DQB1, HLA-DRB1, IFNG, IL10, TNF
2tuberculosis30.2IFNG, IL10, TNF
3leprosy29.4HLA-A, HLA-B, IFNG, IL10, TNF
4hiv-129.3CCR2, CCR5, CXCL12, HLA-A, IFNG, IL10
5aplastic anemia29.1CSF2, HLA-A, HLA-B, HLA-DRB1, IFNG, TNF
6rheumatoid arthritis28.6CCR2, CSF2, CXCL12, HLA-B, HLA-DQB1, HLA-DRB1
7retinitis11.4
8acquired immunodeficiency syndrome10.8
9uveitis10.7
10retinal detachment10.6
11cytomegalovirus infection10.6
12spiradenoma10.6
13eye disease10.6
14retinal disease10.6
15cytomegalic inclusion disease10.6
16human immunodeficiency virus infectious disease10.5
17ipex syndrome10.5
18child syndrome10.5
19globe disease10.5
20kid syndrome10.5
21leukemia10.4
22hematopoietic stem cell transplantation10.3
23retinal vein occlusion10.3
24central retinal vein occlusion10.3
25lymphoblastic leukemia10.3
26cocaine embryofetopathy10.3CSF2, IFNG
27mental retardation, autosomal dominant 710.3IL10, IL10RA
28good syndrome10.3
29lupus erythematosus10.3
30sensorineural hearing loss10.3IFNG, IL10
31functionless pituitary adenoma10.3CSF2, IFNG
32intellectual disability-obesity-prognathism-eye and skin anomalies syndrome10.3HLA-DQB1, IFNG
33graft-versus-host disease, protection against10.3IFNG, IL10
34wild type abeta2m amyloidosis10.3CSF2, IL10
35punctate porokeratosis10.2IL10, TNF
36tucker syndrome10.2HLA-DQB1, HLA-DRB1
37primary progressive freezing gait10.2IL10, TNF
38choroiditis10.2
39nutritional deficiency disease10.2
40sexual disorder10.2
41anterior uveitis10.2
42congenital cytomegalovirus10.2
43drug rash with eosinophilia and systemic symptoms10.2
44stargardt macular degeneration absent or hypoplastic corpus callosum mental retardation and dysmorphic features10.2IFNG, TNF
45autoimmune oophoritis10.2IFNG, TNF
46buruli ulcer10.2IFNG, IL10
47testicular monophasic choriocarcinoma10.2HLA-DQB1, HLA-DRB1
48lichen planus pemphigoides10.2HLA-DQB1, HLA-DRB1
49multifocal lymphangioendotheliomatosis with thrombocytopenia10.2IL10, TNF
50heavy chain deposition disease10.2HLA-DQB1, HLA-DRB1

Graphical network of the top 20 diseases related to Cytomegalovirus Retinitis:



Diseases related to cytomegalovirus retinitis

Symptoms for Cytomegalovirus Retinitis

About this section

Drugs & Therapeutics for Cytomegalovirus Retinitis

About this section

Drugs for Cytomegalovirus Retinitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 22)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
FoscarnetapprovedPhase 4, Phase 3, Phase 2, Phase 13063585-09-13415
Synonyms:
1nki
34156-56-4
4428-95-9
4428-95-9 (Parent)
63585-09-1
63585-09-1 (tri-hydrochloride salt)
79510_FLUKA
A 29622
A-29622
AC-2085
AC1L1FVT
AC1L2C37
AC1L5400
AC1NB82R
AC1Q1UNV
AR-1L5079
Ambap63585-09-1
BSPBio_003067
C06456
CHEBI:127780
CHEBI:141644
CHEBI:60269
CHEMBL666
CHEMBL754
CID169569
CID3415
CID44561
Carboxyphosphonic acid
D00579
D02267
DB00529
DRG-0017
Dihydroxyphosphinecarboxylic acid oxide
Dihydroxyphosphinecarboxylic acid oxide and MSL, neutralizing monoclonal antibody
Dihydroxyphosphinecarboxylic acid oxide trisodium salt
Dihydroxyphosphinecarboxylic acid oxide trisodium salt hexahydrate
DivK1c_000915
EHB 776
EHB-776
FOSCARNET SODIUM
Formic acid, phosphono-, trisodium salt, hexahydrate
Forscarnet sodium
Foscarmet
Foscarnet
Foscarnet & IFN-.ALPHA.
Foscarnet Sodium
Foscarnet sodico
Foscarnet sodico [Spanish]
Foscarnet sodique
Foscarnet sodique [French]
Foscarnet sodique [INN-French]
Foscarnet sodium
Foscarnet sodium (USAN/INN)
Foscarnet sodium [USAN:INN:BAN]
Foscarnet sodium hydrate
Foscarnet sodium hydrate (JAN)
Foscarneto sodico
Foscarneto sodico [INN-Spanish]
Foscarnetum natricum
Foscarnetum natricum [INN-Latin]
Foscarnetum natricum [Latin]
Foscavir
Foscavir (TN)
HMS1921D18
HMS2092N15
 
HMS502N17
HS-0008
IDI1_000915
KBio1_000915
KBio2_001839
KBio2_004407
KBio2_006975
KBio3_002567
KBioGR_001419
KBioSS_001839
LS-105952
LS-105953
LS-183979
LS-187063
LS-187793
MSL & PFA
MolPort-003-665-560
MolPort-003-895-968
NCGC00094941-01
NCGC00094941-02
NChemBio.2007.9-comp7
NINDS_000915
NSC313410
P6801_ALDRICH
P6801_SIGMA
PFA & rIFN.alpha.A
Phgosphonocarboxylic acid
Phosphinecarboxylic acid, dihydroxy-, oxide
Phosphinecarboxylic acid, dihydroxy-, oxide, trisodium salt
Phosphinecarboxylic acid, dihydroxy-, oxide, trisodium salt, hexahydrate
Phosphonoformate
Phosphonoformate(trisodium) & Recombinant Alpha-A Interferon
Phosphonoformic acid
Phosphonoformic acid & IFN-.ALPHA.
Phosphonoformic acid trisodium salt hexahydrate
Phosphonoformic acid, trisodium salt
Phosphonoformic acid, trisodium salt, hexahydrate
Phosphonomethanoic acid
Prestwick_1024
SPBio_000735
SPECTRUM1502019
Sodium phosphonoformate tribasic hexahydrate
Spectrum2_000668
Spectrum3_001484
Spectrum4_000840
Spectrum5_000932
Spectrum_001359
Triapten
Trisodium carboxyphosphate
Trisodium phosphonoformate
Trisodium phosphonoformate hexahydrate
Trisodium phosphonoformte hexahydrate
UNII-364P9RVW4X
UNII-964YS0OOG1
Virudin
dihydroxyphosphanecarboxylic acid oxide
foscarnet
foscarnet sodium hexahydrate
phosphonomethanoic acid
sodium dioxidophosphanecarboxylate oxide hydrate(3:1:6)
trisodium carboxyphosphate (anhydrous)
trisodium dioxidophosphanecarboxylate oxide
trisodium dioxidophosphinecarboxylate oxide
trisodium phosphonatoformate
trisodium phosphonatoformate hexahydrate
trisodium phosphonoformate (anhydrous)
2
ProbenecidapprovedPhase 4, Phase 2, Phase 12757-66-94911
Synonyms:
4-((Dipropylamino)sulfonyl)benzoic acid
4-(Di-N-propylsulfamoyl)benzoesaeure
4-(Di-n-propylsulfamoyl)benzoesaeure
4-(Dipropylsulfamoyl)benzoic acid
4-(N,N-Dipropylsulfamoyl)benzoesaeure
4-[(dipropylamino)sulfonyl]benzoic acid
57-66-9
AB00052080
AC-2023
AC1L1J86
AC1Q2XQM
AC1Q2XQN
AI3-50078
AKOS000165123
Apurina
BIDD:GT0626
BIDD:PXR0092
BPBio1_000643
BRD-K95237249-001-05-9
BRN 2815775
BSPBio_000583
BSPBio_002227
Bencid
Benecid
Benemid
Benemid (TN)
Benemide
Benuryl
Biokanol Brand of Probenecid
C07372
C13H19NO4S
CAS-57-66-9
CCRIS 3643
CHEBI:177474
CHEMBL897
CID4911
CPD000058280
Col-BENEMID
Col-Probenecid
ColBenemid (co mponent of)
ColBenemid (component of)
Colbenemid
D00475
D011339
DB01032
DivK1c_000056
EINECS 200-344-3
HMS1569N05
HMS1920J22
HMS2092C03
HMS500C18
HSDB 3387
I01-1905
ICN Brand of Probenecid
IDI1_000056
IDIS Brand of Probenecid
KBio1_000056
KBio2_001314
KBio2_003882
KBio2_006450
KBio3_001727
KBioGR_000971
KBioSS_001314
LS-33
MLS000028496
MLS001076472
Major Brand of Probenecid
Martec Brand of Probenecid
Merck Brand of Probenecid
MolPort-000-145-935
NCGC00016251-01
NCGC00016251-02
NCGC00023829-03
 
NCGC00023829-04
NCGC00023829-05
NCGC00023829-06
NCI-C56097
NINDS_000056
NSC 18786
NSC18786
Ophthalmic Brand of Probenecid
Oprea1_416955
P-(Dipropylsulfamoyl)benzoic acid
P8761_SIGMA
Panuric
Parabenem
Parmed Brand of Probenecid
Polycillin-BRB
Polycillin-PRB
Polycillin-PRB (component of)
Prestwick0_000542
Prestwick1_000542
Prestwick2_000542
Prestwick3_000542
Prestwick_809
Pro-Cid
Probalan
Probampacin
Probecid
Proben
Proben-C
Probenecid
Probenecid (JP15/USP/INN)
Probenecid Acid
Probenecid Major Brand
Probenecid Martec Brand
Probenecid Parmed Brand
Probenecid Weimer
Probenecid Zenith Brand
Probenecid [INN:BAN:JAN]
Probenecid acid
Probenecida
Probenecida [INN-Spanish]
Probenecide
Probenecide [INN-French]
Probenecidum
Probenecidum [INN-Latin]
Probenemid
Probenicid
Probenid
Probexin
Prolongine
Robenecid
SAM002554923
SBB028597
SMR000058280
SPBio_001327
SPBio_002504
SPECTRUM1500502
Spectrum2_001294
Spectrum3_000554
Spectrum4_000486
Spectrum5_001419
Spectrum_000834
Sulprin
Synergid R
Tubophan
UNII-PO572Z7917
Uricosid
Urocid
Valdecasas Brand of Probenecid
WLN: QVR DSWN3&3
Zenith Brand of Probenecid
p-(Dipropylsulfamoyl)benzoic acid
p-(Dipropylsulfamyl)benzoic acid
p-[Dipropylsulfamoyl]benzoic acid
probenecid
probenicid
3
Ganciclovirapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 113982410-32-03454
Synonyms:
106931-35-5
107910-75-8 (mono-hydrochloride salt)
2'-NDG
2'-Nor-2'-deoxyguanosine
2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol
2-Amino-1,9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-6-H-purin-6-one
2-Amino-9-(2-hydroxy-1-hydroxymethyl-ethoxymethyl)-1,9-dihydro-purin-6-one
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol
2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-3H-purin-6-one
2-amino-9-(2-Hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone
2-amino-9-(2-hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone
2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-1,9-dihydro-6H-purin-6-one
2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6,9-dihydro-3H-purin-6-one
82410-32-0
86357-12-2
9-((1,3-Dihydroxy-2-propoxy)methyl)guanine
9-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine
9-(1,3-DIHYDROXY-PROPOXYMETHANE)GUANINE
9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine
9-[(1,3-dihydroxy-2-propoxy)methyl]guanine
96551-29-0
AC-12604
AC1L1FZ2
AC1Q52OB
AKOS004119898
BB_NC-1042
BIDD:GT0783
BIOLF-62
BPBio1_000877
BSPBio_000797
BW 759
BW 759U
BW-759U
BW-795
BW-B 759U
Biolf 62
CAS-82410-32-0
CCRIS 9212
CHEBI:465284
CHEMBL182
CID3454
CPD000058324
Citovirax
Cymevan
Cymeven
Cymevene
Cytovene
Cytovene (TN)
Cytovene IV
Cytovene-IV
D00333
DB01004
DRG-0018
EU-0100539
 
G 2536
G2536_SIGMA
GA2
GANCICLOVIR SODIUM
GCV & 1110U81
GCV & MSL
Ganciclovir
Ganciclovir & C34-dgA immunotoxin
Ganciclovir & D5-dgA immunotoxin
Ganciclovir (JAN/USP/INN)
Ganciclovir Sodium
Ganciclovir [USAN:INN:BAN:JAN]
Ganciclovirum
Ganciclovirum [Latin]
Gancyclovir
Guanine, 9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)- and MSL, neutralizing monoclonal antibody
HHEMG
HMS1570H19
HMS2090K08
HSDB 6512
Hydroxyacyclovir
I07-0010
IN1478
LS-73939
Lopac-G-2536
Lopac0_000539
MB3795
MLS000028481
MLS001077349
MolPort-000-758-398
MolPort-002-507-301
NCGC00015471-01
NCGC00015471-02
NCGC00015471-03
NCGC00015471-06
NCGC00093928-01
NCGC00093928-02
NCGC00168567-01
PDSP1_000816
PDSP2_000803
Prestwick0_000839
Prestwick1_000839
Prestwick2_000839
Prestwick3_000839
Prestwick_1068
RS-21592
SAM002548936
SMP2_000038
SMR000058324
SPBio_002718
ST-605
STK801910
UNII-P9G3CKZ4P5
Virgan
Vitrasert
Vitrasert (TN)
ZINC00001505
Zirgan
ganciclovir
nchembio.87-comp3
4
CidofovirapprovedPhase 4, Phase 3, Phase 2, Phase 130113852-37-260613
Synonyms:
(2S)-3-Hydroxy-2-phosphonylmethoxypropyl-cytosine
(S)-(3-(4-amino-2-Oxopyrimidin-1(2H)-yl)-1-hydroxypropan-2-yloxy)methylphosphonic acid
(S)-1-(3-Hydroxy-2-phosphonomethoxypropyl)cytosine
(S)-1-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine
(S)-1-[3-Hydroxy-2-(phosphonylmethoxy)propyl]cytosine
(S)-1-[3-hydroxy-2-(phosphonylmethoxy)-propyl]cytosine
(S)-2-(4-Amino-2-oxo-1(2H)-pyrimidinyl-1-(hydroxymethyl)ethoxy)methyl phosphonic acid
(S)-HPMPC
(s)-[[2-(4-amino-2-oxo-1(2h)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic acid
({[(2S)-1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid
({[(S)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid
1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine
1-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine
1-[(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]-cytosine dihydrate
1-[(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine
113852-37-2
120362-37-0 (hydrochloride salt)
149394-66-1
AC-1666
AC1L1TLB
AC1Q6C68
AKOS005145721
C8H14N3O6P
CDV
CHEBI:3696
 
CHEMBL152
CID60613
Cidofovir
Cidofovir (Vistide)
Cidofovir (anhydrous)
Cidofovir Anhydrous
Cidofovir anhydrous
Cidofovirum
DB00369
Forvade
GS 0504
GS 504
GS-0504
GS-504
GS504
HPMPC
HSDB 7115
LS-106432
MolPort-005-935-597
NSC742135
S1516_Selleck
UNII-768M1V522C
Vistide
Vistide, Cidofovir
[(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid
[(S)-2-(4-Amino-2-oxo-2H-pyrimidin-1-yl)-1-hydroxymethyl-ethoxymethyl]-phosphonic acid
[[(S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic acid
5
Phosphonoacetic AcidexperimentalPhase 4, Phase 3, Phase 2, Phase 1304408-78-0546
Synonyms:
Carboxymethanephosphonate
Carboxymethanephosphonic acid
Disodium carboxymethylphosphonate
Disodium phosphonoacetate
Disodium phosphonoacetate monohydrate
Fosfonet
Fosfonet sodium
 
Fosfonoacetate
Fosfonoacetic acid
Lopac-P-6909
PAE
PPA
Phosphonacetate
Phosphonacetic acid
Phosphonoacetate
Phosphonoacetic acid
6
Valganciclovirapproved, investigationalPhase 3, Phase 275175865-60-864147
Synonyms:
175865-60-8
5-Amino-3-[1-(hydroxymethyl)-2-(L-valyloxy)ethoxymethyl]-6,7-dihydro-3H-imidazo[4,5-d]pyrimidin-7-one
AC1L20JF
AC1Q63EV
C14H22N6O5
CID64147
Cymeval
D02495
DB01610
I06-1704
L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)-3-hydroxypropyl ester
 
L-Valine, ester with ganciclovir
L-valine, ester with ganciclovir
LS-173677
NCGC00168779-01
RO1079070/194
RS 79070
UNII-GCU97FKN3R
Valcyte
Valganciclovir
Valganciclovir (INN)
Valganciclovir (Oral)
Valganciclovir [INN:BAN]
[2-[(2-amino-6-oxo-3H-purin-9-yl)methoxy]-3-hydroxypropyl] (2S)-2-amino-3-methylbutanoate
7AcyclovirPhase 3149
8
NelfinavirapprovedPhase 2138159989-64-764143
Synonyms:
(3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylsulfanylbutyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide
(3S-(2(2S*,3S*),3alpha,4abeta,8abeta))-N-(1,1-Dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-3-isoquinolinecarboxamide
159989-64-7
159989-65-8 (monomethane sulfonate (salt))
1UN
1ohr
2-[2-HYDROXY-3-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-4-PHENYL SULFANYL-BUTYL]-DECAHYDRO-ISOQUINOLINE-3-CARBOXYLIC ACID TERT-BUTYLAMIDE
AC-20032
AC1L20J6
AG 1343
AG1343
AG1343 (*Mesylate salt*)
AG1346
AKOS000280862
BIDD:GT0395
BIDD:PXR0143
C07257
C32H45N3O4S
CHEMBL584
CID64143
D08259
DB00220
LS-85417
MLS001195634
 
MLS001304729
Met-SDF-1.beta. & Nelfinavir
Met-Stromal Cell-derived Factor-1.beta. (Human) & Nelfinavir
MolPort-000-883-833
MolPort-002-885-844
NCGC00090782-03
NCGC00090782-04
NELFINAVIR MESYLATE AG1343
NFV
NLF
NSC722664
NSC747167
Nelfinavir
Nelfinavir (INN)
Nelfinavir Monomethane Sulfonate
Nelfinavir [BAN:INN]
Nelfinavir [INN:BAN]
Nelfinavir mesylate
SMR000596515
UNII-HO3OGH5D7I
VRX496
Viracept
Viracept (TM)(*Mesylate salt*)
Viracept (TN)
ag1343
nelfinavir
9FiacitabinePhase 21
10FomivirsenPhase 24
11
AldesleukinapprovedPhase 137285898-30-2
Synonyms:
IL-2
Interleukin-2 precursor
 
Proleukin
T-cell growth factor
TCGF
12Interleukin-2Phase 1472
13
Mycophenolic acidapproved86424280-93-1446541
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
Melbex
 
Micofenolico acido
Mycophenoic acid
Mycophenolate
Mycophenolic Acid
Mycophenolsaeure
Myfortic
14
Interferon beta-1bapproved80145155-23-3
Synonyms:
Betaseron
Extavia
 
Fibroblast interferon
IFN-beta
Interferon beta precursor
15
Zidovudineapproved48930516-87-135370
Synonyms:
-Azido-3&prime
-deoxythymidine
1-(3-Azido-2,3-dideoxy-beta-D-ribofuranosyl)thymine
3&prime
3' Azido 2',3' Dideoxythymidine
3' Azido 3' deoxythymidine
3'-Azido-2',3'-Dideoxythymidine
3'-Azido-3'-deoxythymidine
3'-Azido-3'-deoxythymidine & Concanavalin A
3'-Azido-3'-deoxythymidine & Erythropoietin
3'-Azido-3'-deoxythymidine & Heteropolyoxotungstate PM-19
3'-Azido-3'-deoxythymidine & Interleukin-1
3'-Azido-3'-deoxythymidine & Interleukin-2
3'-Azido-3'-deoxythymidine & Interleukin-6
3'-Azido-3'-deoxythymidine & Lithium & Erythropoietin
3'-Azido-3'-deoxythymidine & Lithium & Interleukin-1
3'-Azido-3'-deoxythymidine & Lithium & Interleukin-6
3'-Azido-3'-deoxythymidine & Lymphoblastoid Interferon
3'-Azido-3'-deoxythymidine & Sho-Saiko-To
3'-Azido-3'-deoxythymidine (AIDS)
3'-Azido-3'deoxythymidine & Interferon .alpha.
3'-Azidothymidine
3'-Deoxy-3'-azidothymidine
3'-azido-3'-deoxythymidine, AZT
3-Azido-3-deoxythymidine
30516-87-1
399024-19-2
A2169_SIGMA
AC1L1TKL
AC1Q2OEK
AZT
AZT & CD4(178)-PE 40
AZT & Colony-stimulating factor 2
AZT & Concanavalin A (ConA)
AZT & EPO
AZT & GM-CSF
AZT & HPA
AZT & IFN.alpha.
AZT & IL-1
AZT & IL-2
AZT & IL-6
AZT & Interferon-.alpha.-2
AZT & Li & EPO
AZT & Li & GM-CSF
AZT & Li & IL-1
AZT & Li & IL-6
AZT & Lymphoblastoid Interferon
AZT & NP (from PHCA or HSA)
AZT & PM-19
AZT & SST
AZT & rIFN.alpha.2
AZT & rsCD4 & rIFN.alpha.A
AZT & rsT4
AZT & sCD4
AZT & srCD4
AZT (Antiviral)
AZT Antiviral
AZT TRANSPLACENTAL CARCINOGENESIS STUDY
AZT+PRO 140
AZT, Antiviral
Antiviral AZT
Apo-Zidovudine
Azidothymidine
Aztec
BB_NC-1012
BPBio1_000403
BRD-K72903603-001-04-6
BSPBio_000365
BSPBio_003153
BW A509U
BW-A 509U
BW-A-509U
BW-A509U
BWA 509U
BWA-509U
BWA509U
C07210
CCRIS 105
CHEBI:10110
CHEBI:127307
CHEMBL129
CID35370
CPD000058351
 
Compound S
Cpd S
D00413
D015215
DB00495
DRG-0004
DS-4152 & AZT
DivK1c_000524
HMS1921J20
HMS2090G11
HMS2092D06
HMS501K06
HSDB 6515
IDI1_000524
Interferon AD + 3'-azido-3'-deoxythymidine
Intron A & AZT
K7 [P Ti2 W10 O40]
KBio1_000524
KBio2_001828
KBio2_004396
KBio2_006964
KBio3_002653
KBioGR_000703
KBioSS_001828
LS-1159
Liposomal AZT-SN-1
Liposomal AZT-SN-3
MLS000028548
MLS001055351
MLS001076358
MLS002153202
MLS002222249
Met-SDF-1.beta. & AZT
Met-SDF-1.beta. & Zidovudine
MolPort-002-507-286
NCGC00023945-03
NCGC00023945-04
NCGC00023945-05
NCGC00023945-08
NCGC00178237-01
NCGC00178237-02
NINDS_000524
NSC 602670
Novo-Azt
PC-SOD+AZT
Prestwick3_000333
Propolis+AZT
Racemic Liposomal AZT
Retrovir
Retrovir (TN)
Retrovir(TM)
SAM002548971
SMR000058351
SN-1-dipalmitoylglycerophospho-AZT (in a lipid vesicle)
SN-3-dipalmitoylglycerophospho-AZT (in a lipid vesicle)
SPBio_000834
SPECTRUM1502109
STK801891
Spectrum2_000927
Spectrum3_001507
Spectrum4_000332
Spectrum5_001101
Spectrum_001348
UNII-4B9XT59T7S
ZDV
ZIDOVUDINE [AZT]
ZINC03779042
ZVD
Zidovudin
Zidovudina
Zidovudina [Spanish]
Zidovudine
Zidovudine (JAN/USP/INN)
Zidovudine EP III
Zidovudine [USAN:INN:BAN:JAN]
Zidovudine+PRO 140
Zidovudinum
Zidovudinum [Latin]
antiviral
azidodeoxythymidine
rIFN-beta seron & AZT
racemic-dipalmitoylglycerophospho-AZT (in a lipid vesicle)
zidovudin
zidovudine
16
Mycophenolate mofetilapproved, investigational864128794-94-55281078
Synonyms:
115007-34-6
128794-94-5
140401-05-4
2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate
2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
AC-1562
AC1NQXZW
AC1Q6O6X
AR-1J6939
BB_NC-2566
C07908
C23H31NO7
CHEMBL1456
CID5281078
CellCept
CellCept, RS 61443, TM-MMF, Mycophenolate mofetil
Cellcept
Cellcept (TN)
D00752
DB00688
HMS2090A03
 
HSDB 7436
I01-0898
I06-1947
LS-172272
LS-75572
ME-MPA
MMF
MMF CellCept(TM)
MolPort-000-883-800
Munoloc
Mycophenolate Mofetil
Mycophenolate mofetil (JAN/USAN)
Mycophenolic acid morpholinoethyl ester
Mycophenylate mofetil
NCGC00159459-02
NCGC00159459-03
NSC724229
R-99
RS 61443
RS-61443
RS-61443-190
S1501_Selleck
TL8000648
TM-MMF
UNII-9242ECW6R0
ZINC21297660
mycophenolate mofetil
17
Ampicillinapproved5069-53-46249
Synonyms:
(2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(2S,5R,6R)-6-{[(2R)-2-amino-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(2S,5R,6R)-6-{[(2R)-2-amino-2-phenylethanoyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
1h8s
33604-21-6
37234-64-3
47355-94-2
50584-05-9
6-(D(-)-alpha-Aminophenylacetamido)penicillanic acid
6-(D-(2-amino-2-Phenylacetamido))-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid
6-(a-Aminophenylacetamido)penicillanic acid
6-D(-)-alpha-Aminophenylacetamido-penicillanic acid
6-[(Aminophenylacetyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 9CI
69-52-3 (mono-hydrochloride salt)
69-53-4
6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carbonyl
6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carboxylic acid
7177-48-2 (TRIHYDRATE)
800-79-3
8056-87-9
96707-69-6
98520-55-9
A9393_SIGMA
AB-PC
AB-PC Sol
ABPC
AC-14075
AC1L1M46
AMP
AMPI
AMPICILLIN (SEE ALSO AMPICILLIN TRIHYDRATE 7177-48-2)
AP
AY 6108
AY 6108
AY-6108
Acillin
Adobacillin
Alpen
Amblosin
Amcill
Amfipen
Amfipen V
Amfipen v
Aminobenzylpenicillin
Amipenix S
Ampen
Ampi-Co
Ampi-Tab
Ampi-bol
Ampi-co
Ampi-tab
Ampichel
Ampicil
Ampicilina
Ampicilina [INN-Spanish]
Ampicillin
Ampicillin (USP/INN)
Ampicillin A
Ampicillin Acid
Ampicillin Anhydrate
Ampicillin Anhydrous
Ampicillin Base
Ampicillin Sodium
Ampicillin Trihydrate
Ampicillin [USAN:BAN:INN:JAN]
Ampicillin [USAN:INN:BAN:JAN]
Ampicillin [Usan:Ban:Inn:Jan]
Ampicillin acid
Ampicillin anhydrate
Ampicillin sodium
Ampicillina
Ampicillina [DCIT]
Ampicillina [Dcit]
Ampicilline
Ampicilline [INN-French]
Ampicillinum
Ampicillinum [INN-Latin]
Ampicin
Ampifarm
Ampikel
Ampimed
Ampipenin
Ampipenin, nt3
Ampiscel
Ampisyn
Ampivax
Ampivet
Amplacilina
Amplin
Amplipenyl
Amplisom
Amplital
Ampy-Penyl
Anhydrous Ampicillin
Anhydrous ampicillin
Anhydrous ampicillin (JP15)
Austrapen
BA 7305
BIDD:GT0184
BPBio1_000142
BRL 1341
BRL-1341
BSPBio_000128
BSPBio_001862
Bayer 5427
Binotal
Bonapicillin
Britacil
C06574
CHEBI:28971
CHEBI:53713
CHEMBL174
CID6249
Campicillin
Cimex
Copharcilin
D-(-)-6-(alpha-Aminophenylacetamido)penicillanic acid
D-(-)-6-(alpha-aminophenylacetamido)penicillanic acid
D-(-)-Ampicillin
D-(-)-alpha-Aminobenzylpenicillin
D-(-)-alpha-Aminopenicillin
D-(-)-ampicillin
D-(−)-6-(α-aminophenylacetamido)penicillanic acid
D-(−)-ampicillin
D-Ampicillin
D-Cillin
D-a-Aminobenzylpenicillin
D00204
DB00415
Delcillin
Deripen
 
DivK1c_000466
Divercillin
Doktacillin
Duphacillin
EINECS 200-709-7
Geocillin
Grampenil
Guicitrina
Guicitrine
HI 63
HMS2090I11
HSDB 3009
IDI1_000466
KBio1_000466
KBio2_000430
KBio2_002998
KBio2_005566
KBio3_001362
KBioGR_000598
KBioSS_000430
KS-R1
LS-1586
LS-169948
Lifeampil
MLS000028405
MLS001074168
Magnapen
Marcillin
MolPort-001-794-635
Morepen
NCGC00023282-05
NCGC00023282-06
NINDS_000466
NSC 528986
NSC-528986
NSC528986
Norobrittin
Novo-ampicillin
Nuvapen
OMNIPEN (AMPICILLIN)
Olin Kid
Olin kid
Omnipen
Omnipen (TN)
Omnipen-N
Orbicilina
P 50
P-50
Pen A
Pen A Oral
Pen Ampil
Pen a
Pen ampil
Penbristol
Penbritin
Penbritin paediatric
Penbritin syrup
Penbritin-S
Penbrock
Penicillin, Aminobenzyl
Penicline
Penimic
Pensyn
Pentrex
Pentrexl
Pentrexyl
Pentritin
Pfizerpen A
Pfizerpen a
Pfizerpen-A
Polycillin
Polycillin-N
Polyflex (Veterinary)
Ponecil
Prestwick0_000114
Prestwick1_000114
Prestwick2_000114
Prestwick3_000114
Princillin
Principen
Principen '125'
Principen '250'
Principen '500'
QIDamp
Qidamp
Racenacillin
Ro-Ampen
Ro-ampen
Rosampline
Roscillin
SBB063111
SK-Ampicillin
SK-ampicillin
SMP1_000211
SMR000058352
SPBio_000818
SPBio_002067
SQ 17382
Semicillin
Semicillin R
Servicillin
Spectrum2_000769
Spectrum3_000301
Spectrum4_000149
Spectrum5_000814
Spectrum_000050
Sumipanto
Supen
Synpenin
Texcillin
Tokiocillin
Tolomol
Totacillin
Totacillin (sodium)
Totacillin-N
Totalciclina
Totapen
Trifacilina
UNII-7C782967RD
Ukapen
Ultrabion
Ultrabron
Vampen
Viccillin
Viccillin S
Vidocillin
Vidopen
WY-5103
Wypicil
alpha-Aminobenzylpenicillin
ampicillanyl
ampicillin
anhydrous ampicillin
18Tin Fluorides188
19Interferon Type I13
20Interferon-beta244
21Gamma-Globulins22
22Emetics159

Interventional clinical trials:

(show top 50)    (show all 71)
idNameStatusNCT IDPhase
1Comparison of Two Drugs, Cidofovir and Ganciclovir, in Treating Patients With AIDS Who Have CMV RetinitisCompletedNCT00000894Phase 4
2A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium)CompletedNCT00002125Phase 4
3Pharmacokinetics of Cidofovir During Continuous Venovenous HemofiltrationCompletedNCT01866397Phase 4
4Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT)CompletedNCT00000134Phase 3
5A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDSCompletedNCT00000688Phase 3
6A Treatment Protocol for the Use of Intravenous Ganciclovir in AIDS Patients With Immediately Sight-Threatening CMV RetinitisCompletedNCT00000698Phase 3
7Studies of the Ocular Complications of AIDS (SOCA)--Monoclonal Antibody CMV Retinitis Trial (MACRT)CompletedNCT00000135Phase 2, Phase 3
8Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)CompletedNCT00000143Phase 3
9Studies of the Ocular Complications of AIDS (SOCA)--Foscarnet-Ganciclovir CMV Retinitis Trial (FGCRT)CompletedNCT00000136Phase 3
10Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV RetinitisCompletedNCT00002070Phase 3
11Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT)CompletedNCT00000142Phase 2, Phase 3
12Ganciclovir Implant Study for Cytomegalovirus RetinitisCompletedNCT00000118Phase 3
13A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the EyesCompletedNCT00002377Phase 3
14Valganciclovir in Prevention of Cytomegalovirus (CMV) Reactivation Following Allogeneic-Stem Cell Transplantation (SCT)CompletedNCT00330018Phase 3
15Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by InjectionActive, not recruitingNCT00017784Phase 3
16A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR )CompletedNCT00002156Phase 2
17Phase II Randomized Study of Cidofovir for Peripheral Cytomegalovirus RetinitisCompletedNCT00004794Phase 2
18A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment FailureCompletedNCT00000691Phase 2
19A Study of Viracept in AIDS Patients With Cytomegalovirus RetinitisCompletedNCT00002169Phase 2
20The Safety and Effectiveness of ISIS 2922 in Patients With AIDS Who Have Cytomegalovirus (CMV) of the EyesCompletedNCT00002356Phase 2
21CMV Retinitis Retreatment TrialCompletedNCT00000766Phase 2
22The Safety and Effectiveness of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDSCompletedNCT00002437Phase 2
23A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT)CompletedNCT00000836Phase 2
24Comparison of Two Methods in the Treatment of Cytomegalovirus of the Eyes in Patients With AIDSCompletedNCT00001061Phase 2
25The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIVCompletedNCT00001034Phase 2
26The Safety and Effectiveness of FIAC in the Treatment of Cytomegalovirus (CMV) in Patients With AIDSCompletedNCT00000981Phase 2
27Congenital CMV and Hearing Loss in Children up to 4 Years of Age: Treating With Valganciclovir TherapyRecruitingNCT01649869Phase 2
28Anti-virus Treatment Following Bone Marrow TransplantRecruitingNCT02048332Phase 1, Phase 2
29Third Party Anti-Viral Cytotoxic T-CellsRecruitingNCT02532452Phase 2
30Cidofovir in Renal Transplant Recipients With BKVNTerminatedNCT00138424Phase 1, Phase 2
31A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Who Cannot Use GanciclovirWithdrawnNCT00000697Phase 2
32A Study of Ganciclovir in the Treatment of Cytomegalovirus of the EyesCompletedNCT00001062Phase 1
33A Phase I/II Open-Labelled Trial of Intravitreal Ganciclovir Salvage Therapy for AIDS Patients With Active CMV Retinitis Who Are Intolerant of Systemic TherapyCompletedNCT00000673Phase 1
34Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency SyndromeCompletedNCT00000726Phase 1
35A Phase I/II Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV RetinitisCompletedNCT00002016Phase 1
36A Study of Foscarnet Plus Ganciclovir in the Treatment of Cytomegalovirus of the Eye in Patients With AIDS Who Have Already Been Treated With GanciclovirCompletedNCT00000970Phase 1
37A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) RetinitisCompletedNCT00002321Phase 1
38A Phase I Pharmacokinetic and Tolerance Study of 28-Day Regimens of Oral GanciclovirCompletedNCT00000668Phase 1
39A Pharmacokinetic and Tolerance Study of Oral Ganciclovir in HIV-Infected Children With Asymptomatic Cytomegalovirus Infection and Low CD4 Cell Counts or Quiescent Cytomegalovirus DiseaseCompletedNCT00000805Phase 1
40A Study of Cidofovir in HIV-Infected Children With Cytomegalovirus (CMV) DiseaseWithdrawnNCT00000881Phase 1
41A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus RetinitisCompletedNCT00002187
42Suppression of Cytomegalovirus Retinitis Utilizing High Dose Intravenous Acyclovir and Oral Zidovudine in Patients With AIDSCompletedNCT00000693
43A Randomized Controlled Study of the Efficacy and Safety of Maintenance Treatment With Oral Ganciclovir for Newly Diagnosed Cytomegalovirus Retinitis in People With AIDSCompletedNCT00002257
44Efficacy of Elevated CD4 Counts on CMV RetinitisCompletedNCT00091884
45A Study of the Safety and Tolerance of Long-Term Therapy With Intravenous Cytovene (Ganciclovir Sodium) for Cytomegalovirus Retinitis in Persons With AIDSCompletedNCT00002034
46A Randomized, Controlled Study of the Safety and Preventive Efficacy of Oral Ganciclovir When Used in Conjunction With An Intravitreal Ganciclovir Implant in the Treatment of Cytomegalovirus RetinitisCompletedNCT00002134
47A Randomized Study Comparing the Safety and Efficacy of Two Regimens of Oral Ganciclovir to Intravenous Ganciclovir Maintenance Therapy for Cytomegalovirus Retinitis in People With AIDS Who Have Received Prior Ganciclovir TherapyCompletedNCT00002247
48A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDSCompletedNCT00002222
49An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDSCompletedNCT00002142
50Studies of the Ocular Complications of AIDS (SOCA) CMV Retinitis Trial: Foscarnet-Ganciclovir ComponentCompletedNCT00000665

Search NIH Clinical Center for Cytomegalovirus Retinitis

Inferred drug relations via UMLS65/NDF-RT43:

Genetic Tests for Cytomegalovirus Retinitis

About this section

Anatomical Context for Cytomegalovirus Retinitis

About this section

MalaCards organs/tissues related to Cytomegalovirus Retinitis:

33
Eye, Retina, T cells, Bone, Bone marrow, Testes, Endothelial

Animal Models for Cytomegalovirus Retinitis or affiliated genes

About this section

MGI Mouse Phenotypes related to Cytomegalovirus Retinitis:

38 (show all 12)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053888.4CCR2, CD9, CSF2, HLA-DQB1, IFNG, IL10
2MP:00020068.4CCR2, CCR5, CSF2, IFNG, IL10, TNF
3MP:00053818.3CCR2, CCR5, HLA-DQB1, IFNG, IL10, IL10RA
4MP:00053698.3CCR5, CXCL12, HLA-DQB1, IFNG, IL10, TNF
5MP:00053708.0CCR2, CCR5, CXCL12, HLA-DQB1, IFNG, IL10
6MP:00053857.7CCR2, CCR5, CSF2, CXCL12, HLA-DQB1, IFNG
7MP:00030127.6CCR2, CCR5, CXCL12, HLA-B, IFNG, IL10
8MP:00053897.5CCR5, CD9, CSF2, CXCL12, HLA-DQB1, IFNG
9MP:00053847.5CCR2, CCR5, CSF2, CXCL12, HLA-DQB1, IFNG
10MP:00053867.2CCR2, CCR5, CSF2, HLA-B, HLA-DQB1, IFNG
11MP:00053876.0CCR2, CCR5, CD9, CSF2, CXCL12, HLA-B
12MP:00053975.8CCR2, CCR5, CD9, CSF2, CXCL12, HLA-B

Publications for Cytomegalovirus Retinitis

About this section

Articles related to Cytomegalovirus Retinitis:

(show top 50)    (show all 536)
idTitleAuthorsYear
1
Cytomegalovirus Retinitis in a Human Immunodeficiency Virus-negative Cohort: Long-term Management and Complications. (25760914)
2015
2
Cytomegalovirus Retinitis and Uveitis. (26471353)
2015
3
Incidence Rate and Risk Factors for Contralateral Eye Involvement among Patients with AIDS and Cytomegalovirus Retinitis Treated with Local Therapy. (26258284)
2015
4
Herpetic (non-cytomegalovirus) retinal infections in patients with the acquired immunodeficiency syndrome. (23544389)
2013
5
A messenger at the door: cytomegalovirus retinitis in myeloma patients with progressive disease. (23790037)
2013
6
Telemedicine screening for cytomegalovirus retinitis using digital fundus photography. (23756239)
2013
7
Retinal metastasis simulating cytomegalovirus retinitis. (22938704)
2012
8
Risk factors for cytomegalovirus retinitis in patients with cytomegalovirus viremia after hematopoietic stem cell transplantation. (22657564)
2012
9
Evidence for multiple cell death pathways during development of experimental cytomegalovirus retinitis in mice with retrovirus-induced immunosuppression: apoptosis, necroptosis, and pyroptosis. (22837196)
2012
10
The epidemiology and incidence of cytomegalovirus retinitis in the HIV population in Singapore over 6 years. (23074211)
2012
11
Association of host genetic risk factors with the course of cytomegalovirus retinitis in patients infected with human immunodeficiency virus. (21396623)
2011
12
Cytomegalovirus retinitis in an immunocompromised infant: a case report and review of the literature. (21941498)
2011
13
Evaluation of the United States public health service guidelines for discontinuation of anticytomegalovirus therapy after immune recovery in patients with cytomegalovirus retinitis. (21742304)
2011
14
Mortality associated with resistant cytomegalovirus among patients with cytomegalovirus retinitis and AIDS. (19818505)
2010
15
Intravitreal ganciclovir in the management of non-AIDS-related human cytomegalovirus retinitis. (20379302)
2010
16
Good's syndrome in a patient with cytomegalovirus retinitis. (18382022)
2008
17
Increased incidence of cytomegalovirus retinitis after allogeneic hematopoietic stem cell transplantation. (17220797)
2007
18
Cytomegalovirus retinitis following intravitreal injection of triamcinolone: report of two cases. (17403022)
2007
19
Cytomegalovirus retinitis: the neglected disease of the AIDS pandemic. (18052600)
2007
20
Long-term follow-up of a cohort of HIV-infected patients who discontinued maintenance therapy for cytomegalovirus retinitis. (16632459)
2006
21
Indocyanine green angiographic findings in a cytomegalovirus retinitis patient. (16334614)
2005
22
A case of immune recovery vitritis induced by donor leukocyte infusion for the treatment of cytomegalovirus retinitis. (16146543)
2005
23
PCR with the aqueous humor, blood leukocytes and vitreous of patients affected by cytomegalovirus retinitis and immune recovery uveitis. (14688435)
2004
24
Human cytomegalovirus retinitis: pathogenicity, immune evasion and persistence. (12706995)
2003
25
Interleukin-2 immunotherapy of murine cytomegalovirus retinitis during MAIDS correlates with increased intraocular CD8+ T-cell infiltration. (12711843)
2003
26
Mortality risk for patients with cytomegalovirus retinitis and acquired immune deficiency syndrome. (14583871)
2003
27
Visual loss in patients with cytomegalovirus retinitis and acquired immunodeficiency syndrome before widespread availability of highly active antiretroviral therapy. (12523893)
2003
28
Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS. (11931782)
2002
29
HIV and cytomegalovirus viral load and clinical outcomes in AIDS and cytomegalovirus retinitis patients: Monoclonal Antibody Cytomegalovirus Retinitis Trial. (11919489)
2002
30
Protease inhibitor therapy is associated with markedly prolonged time to relapse and improved survival in AIDS patients with cytomegalovirus retinitis. (11564333)
2001
31
Cystoid macular edema in patients with acquired immune deficiency syndrome and cytomegalovirus retinitis. (11071031)
2000
32
Highly active antiretroviral therapy-related immune recovery in AIDS patients with cytomegalovirus retinitis. (10811078)
2000
33
HIV associated cytomegalovirus retinitis in Melbourne, Australia. (10961210)
2000
34
Visual and anatomic outcomes associated with posterior segment complications after ganciclovir implant procedures in patients with AIDS and cytomegalovirus retinitis. (10088738)
1999
35
Cystoid macular edema following immune recovery and treatment with cidofovir for cytomegalovirus retinitis. (10541898)
1999
36
Successive intraocular nocardiosis and cytomegalovirus retinitis after cardiac transplantation. (9682720)
1998
37
Optic nerve head neovascularization in a patient with inactive cytomegalovirus retinitis and immune recovery. (9727534)
1998
38
Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis. (9194724)
1997
39
New therapies for cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. (9109331)
1997
40
Successful use of cidofovir in treating AIDS-related cytomegalovirus retinitis, encephalitis, and esophagitis. (9215660)
1997
41
Antibody alone does not prevent experimental cytomegalovirus retinitis in mice with retrovirus-induced immunodeficiency (MAIDS). (9380340)
1997
42
Convenient twice daily foscarnet in induction therapy of AIDS-associated cytomegalovirus retinitis. The Foscarnet Italian Study Group. (9030380)
1997
43
Cytomegalovirus retinitis: diagnosis and status of systemic therapy. (9058611)
1997
44
An economic evaluation of oral compared with intravenous ganciclovir for maintenance treatment of newly diagnosed cytomegalovirus retinitis in AIDS patients. (8829030)
1996
45
Cytomegalovirus retinitis and viral resistance. Prevalence of resistance at diagnosis, 1994. Cytomegalovirus Retinitis and Viral Resistance Study Group. (8660163)
1996
46
Treatment of cytomegalovirus retinitis: A growing number of options. (22514462)
1996
47
Long survival in AIDS-related cytomegalovirus retinitis. (8680895)
1996
48
Effectiveness of entoptic perimetry for locating peripheral scotomas caused by cytomegalovirus retinitis. (8660166)
1996
49
Treatment of cytomegalovirus retinitis in patients with AIDS. (8678370)
1996
50
Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitis. (1323624)
1992

Variations for Cytomegalovirus Retinitis

About this section

Expression for genes affiliated with Cytomegalovirus Retinitis

About this section
Search GEO for disease gene expression data for Cytomegalovirus Retinitis.

Pathways for genes affiliated with Cytomegalovirus Retinitis

About this section

Pathways related to Cytomegalovirus Retinitis according to GeneCards Suite gene sharing:

(show all 34)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Show member pathways
9.5CSF2, IFNG, TNF
29.5IL10, IL10RA, TNF
39.4IFNG, IL10, TNF
4
Show member pathways
9.4IFNG, IL10, TNF
59.4IFNG, IL10, TNF
69.4HLA-DQB1, HLA-DRB1, IL10
79.4CCR2, IFNG, TNF
89.4CCR2, IFNG, TNF
9
Show member pathways
9.4CSF2, IFNG, IL10, IL10RA
10
Show member pathways
9.2IFNG, IL10, IL10RA, TNF
119.2CSF2, IFNG, IL10, TNF
12
Show member pathways
9.2CSF2, IFNG, IL10, TNF
13
Show member pathways
9.1HLA-A, IFNG, TNF
14
Show member pathways
9.1CCR2, CCR5, CXCL12
159.1CD9, CSF2, HLA-DRB1, TNF
168.8CSF2, HLA-DRB1, IFNG, IL10, TNF
17
B cell receptor signaling pathway (KEGG)
Show member pathways
8.6CSF2, HLA-DRB1, IFNG, IL10, TNF
18
Show member pathways
8.6CCR5, HLA-A, HLA-DRB1, IFNG
198.6CCR2, CXCL12, IFNG, IL10, TNF
208.4HLA-DQB1, HLA-DRB1, IFNG, IL10, IL10RA, TNF
218.3HLA-A, HLA-B, HLA-DQB1, HLA-DRB1
228.3HLA-A, HLA-B, HLA-DQB1, HLA-DRB1
238.2CSF2, CXCL12, HLA-DQB1, HLA-DRB1, IFNG, TNF
24
Show member pathways
8.0CSF2, HLA-A, HLA-B, IFNG, TNF
25
Show member pathways
8.0HLA-A, HLA-B, HLA-DQB1, HLA-DRB1, IFNG
26
Show member pathways
8.0HLA-A, HLA-B, IFNG, IL10, TNF
27
Show member pathways
7.9CCR5, HLA-DQB1, HLA-DRB1, IFNG, IL10, IL10RA
28
Show member pathways
7.8CCR2, CCR5, CSF2, CXCL12, IL10, IL10RA
29
Show member pathways
7.8CCR2, CCR5, CSF2, CXCL12, IL10, IL10RA
307.6CSF2, HLA-A, HLA-B, HLA-DQB1, HLA-DRB1, TNF
31
Show member pathways
7.5CCR2, CCR5, CSF2, CXCL12, IFNG, IL10
32
Show member pathways
7.5HLA-A, HLA-B, HLA-DQB1, HLA-DRB1, IFNG, TNF
337.4HLA-A, HLA-B, HLA-DQB1, HLA-DRB1, IFNG, IL10
34
Show member pathways
6.5CXCL12, HLA-A, HLA-B, HLA-DQB1, HLA-DRB1, IFNG

GO Terms for genes affiliated with Cytomegalovirus Retinitis

About this section

Cellular components related to Cytomegalovirus Retinitis according to GeneCards Suite gene sharing:

(show all 11)
idNameGO IDScoreTop Affiliating Genes
1MHC class II protein complexGO:004261310.3HLA-DQB1, HLA-DRB1
2endocytic vesicle membraneGO:003066610.0CD9, HLA-DQB1, HLA-DRB1
3clathrin-coated endocytic vesicle membraneGO:003066910.0CD9, HLA-DQB1, HLA-DRB1
4MHC class I protein complexGO:00426129.8HLA-A, HLA-B
5integral component of lumenal side of endoplasmic reticulum membraneGO:00715568.9HLA-A, HLA-B, HLA-DQB1, HLA-DRB1
6ER to Golgi transport vesicle membraneGO:00125078.9HLA-A, HLA-B, HLA-DQB1, HLA-DRB1
7external side of plasma membraneGO:00098978.5CCR5, CD9, CXCL12, HLA-DRB1, IFNG, TNF
8extracellular spaceGO:00056158.0CD9, CSF2, CXCL12, IFNG, IFNL4, IL10
9integral component of plasma membraneGO:00058877.4CCR2, CCR5, CD9, HLA-A, HLA-B, HLA-DRB1
10cell surfaceGO:00099867.1CCR5, CD9, HLA-A, HLA-B, HLA-DRB1, TNF
11plasma membraneGO:00058865.9CCR2, CCR5, CD9, CXCL12, HLA-A, HLA-B

Biological processes related to Cytomegalovirus Retinitis according to GeneCards Suite gene sharing:

(show all 37)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of interleukin-23 productionGO:003274710.6CSF2, IFNG
2positive regulation of MHC class II biosynthetic processGO:004534810.5IFNG, IL10
3positive regulation of vitamin D biosynthetic processGO:006055710.5IFNG, TNF
4defense response to protozoanGO:004283210.4IFNG, IL10
5positive regulation of calcidiol 1-monooxygenase activityGO:006055910.4IFNG, TNF
6antigen processing and presentation of peptide or polysaccharide antigen via MHC class IIGO:000250410.4HLA-DQB1, HLA-DRB1
7receptor biosynthetic processGO:003280010.4IL10, TNF
8immunoglobulin production involved in immunoglobulin mediated immune responseGO:000238110.4HLA-DQB1, HLA-DRB1
9positive regulation of chemokine biosynthetic processGO:004508010.4IFNG, TNF
10positive regulation of membrane protein ectodomain proteolysisGO:005104410.4IFNG, TNF
11positive regulation of podosome assemblyGO:007180310.4CSF2, TNF
12negative regulation of cytokine secretion involved in immune responseGO:000274010.4IL10, TNF
13humoral immune response mediated by circulating immunoglobulinGO:000245510.3HLA-DQB1, HLA-DRB1
14negative regulation of interleukin-6 productionGO:003271510.3IL10, TNF
15positive regulation of osteoclast differentiationGO:004567210.2IFNG, TNF
16positive regulation of monocyte chemotaxisGO:009002610.1CCR2, CXCL12
17dendritic cell chemotaxisGO:000240710.0CCR2, CCR5
18negative regulation of growth of symbiont in hostGO:00441309.9IFNG, IL10, TNF
19antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independentGO:00024809.7HLA-A, HLA-B
20antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentGO:00024869.7HLA-A, HLA-B
21positive regulation of T cell mediated cytotoxicityGO:00019169.7HLA-A, HLA-B
22positive regulation of interferon-gamma productionGO:00327299.7CCR2, HLA-A, TNF
23protection from natural killer cell mediated cytotoxicityGO:00422709.7HLA-A, HLA-B
24defense response to bacteriumGO:00427429.5IFNG, IL10, TNF
25positive regulation of cell adhesionGO:00457859.5CXCL12, IFNG, TNF
26chemokine-mediated signaling pathwayGO:00700989.4CCR2, CCR5, CXCL12
27chemotaxisGO:00069359.3CCR2, CCR5, CXCL12
28cell surface receptor signaling pathwayGO:00071669.3CCR5, CD9, IFNG, TNF
29detection of bacteriumGO:00160459.3HLA-A, HLA-B, HLA-DRB1
30inflammatory responseGO:00069549.2CCR2, CCR5, IL10, TNF
31cellular response to lipopolysaccharideGO:00712229.0CCR5, CSF2, IFNG, IL10, TNF
32response to virusGO:00096158.9CXCL12, IFNG, TNF
33interferon-gamma-mediated signaling pathwayGO:00603338.6HLA-A, HLA-B, HLA-DQB1, HLA-DRB1, IFNG
34antigen processing and presentationGO:00198828.5HLA-A, HLA-B, HLA-DQB1, HLA-DRB1, IFNG
35viral processGO:00160327.8CCR2, CCR5, HLA-A, HLA-B, HLA-DRB1
36cytokine-mediated signaling pathwayGO:00192217.4CCR2, HLA-A, HLA-B, HLA-DQB1, HLA-DRB1, IFNG
37immune responseGO:00069555.8CCR2, CCR5, CSF2, CXCL12, HLA-A, HLA-B

Molecular functions related to Cytomegalovirus Retinitis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1MHC class II receptor activityGO:003239510.2HLA-DQB1, HLA-DRB1
2C-C chemokine receptor activityGO:00164939.9CCR2, CCR5
3TAP bindingGO:00469779.5HLA-A, HLA-B
4chemokine receptor activityGO:00049509.3CCR2, CCR5
5cytokine activityGO:00051258.7CSF2, IFNG, IFNL4, IL10, TNF
6peptide antigen bindingGO:00426058.3HLA-A, HLA-B, HLA-DQB1, HLA-DRB1

Sources for Cytomegalovirus Retinitis

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet